Treatments & substances

The Snerva stance on sleep substances

Most sleep aids — prescription and over-the-counter — are symptom management, not curative. CBT-I is curative. Substances treat the night you take them, not the underlying condition. The distinction matters because the treatment plan looks fundamentally different depending on which one you are running.

The marketing-to-evidence ratio in this category is the worst in sleep of any health niche. Melatonin is dosed incorrectly by an estimated ninety-five percent of users. Magnesium is hyped past the evidence. CBD is entirely under-regulated. Generic sleep stacks are sold on Amazon without ingredient transparency, with five-star reviews that bear no relationship to what is actually in the bottle.

There is a short list of substances with real evidence at the right doses, used the right way. Snerva covers those substances honestly in this cluster. Everything else gets named and dismissed in the same breath. We do not run affiliate links on cornerstone editorial pieces, and certainly not in a hub that recommends taking most of these products off the shelf.

Sleep substances belong on the second page of your treatment plan, not the first. The first page is behavioral and unmedicated. The second page exists, occasionally, when the first page is being run well and is not enough on its own. Anything else is a category mistake — and the category mistake is what most of the sleep-aid industry is selling.

The four-tier framework

Snerva organizes sleep substances into four tiers. The tiers are not legal categories — they are evidence-versus-marketing ratios. Each tier has a deep-dive in this cluster.

Tier 1 — Prescription sleep medications

Z-drugs (zolpidem, eszopiclone, zaleplon), benzodiazepines, the orexin antagonists (suvorexant, daridorexant, lemborexant), trazodone, low-dose doxepin. Defensible for short-term acute insomnia under four weeks, with medical supervision and a behavioral plan running in parallel. Tolerance, dependence, and sleep-architecture suppression all show up on longer timelines for the older classes. The newer orexin antagonists are cleaner. Detailed comparison in our CBT-I versus sleeping pills piece.

Tier 2 — Endogenous hormones at exogenous doses (melatonin)

The single most misused substance in the sleep category. The right dose is 0.3 to 0.5 milligrams — roughly an order of magnitude smaller than what most over-the-counter products contain. The right timing is four to six hours before target bedtime, not at bedtime — because melatonin is a chronobiotic, not a sedative. The right use case is circadian phase shifting (jet lag, delayed sleep phase disorder), not sleep onset for the general anxious sleeper. Deep dive: melatonin.

Tier 3 — Minerals and amino acids with real evidence

Magnesium glycinate, glycine, L-theanine, apigenin. Effects are modest. Risk is low. The mechanism in each case is biologically plausible and reasonably well-studied. None of these will fix insomnia. They can support sleep quality at the margins. Form matters more than brand — magnesium glycinate is not the same compound as magnesium citrate (a laxative) or magnesium oxide (poorly absorbed). Deep dive: magnesium and sleep.

Tier 4 — Substances with thin evidence and aggressive marketing

CBD, ashwagandha, valerian, GABA supplements, melatonin gummies, generic sleep stacks, the PM combination formulations stacking acetaminophen with diphenhydramine. Evidence ranges from mixed to nonexistent. Regulation is poor, CBD especially in the US. Marketing is the dominant signal in this tier. Deep dive: CBD and sleep, plus the broader ranking in our OTC sleep aids ranked piece.

Sleep aids are the only category of pill where the marketing makes the underlying condition worse. Branded packaging plus the word sleep on the front is enough to move a substance that has no plausible mechanism.

Over-the-counter, briefly

The OTC aisle is its own ecosystem and the full ranking lives in our OTC sleep aids ranked piece. The short version, in descending order of evidence-to-harm ratio.

At the top of the list: magnesium glycinate at 200 to 400 milligrams elemental magnesium, L-theanine at 100 to 200 milligrams, and apigenin (emerging evidence, promising). These are tier 3 and they are the only OTC choices we recommend without caveats.

In the middle: melatonin, if you can find a 0.3 to 0.5 milligram product and you are using it for circadian phase shifting rather than for sleep onset. Almost no consumer can find that product on the first try. Most settle for 3 or 5 milligrams, which is the wrong dose, taken at the wrong hour.

At the bottom: diphenhydramine (the active ingredient in ZzzQuil and Tylenol PM), doxylamine (Unisom), valerian, chamomile, the PM combination drugs, and most multi-ingredient sleep stacks. Diphenhydramine and doxylamine are first-generation antihistamines with anticholinergic effects; long-term anticholinergic use in adults over sixty-five has been linked in observational data to elevated dementia risk, and tolerance develops within roughly a week of nightly use. The fact that you can buy them next to candy does not make them appropriate for a chronic insomniac who will use them nightly for two years.

Melatonin at 0.3 milligrams is a useful tool. Melatonin at 10 milligrams is an experiment in receptor downregulation conducted by people who do not know they are running it.

What we will not recommend

Most of the sleep-aid landscape gets the same treatment from most health sites: a non-judgmental rundown with mild caveats. Snerva's framework is opinionated and specific. The following get named and dismissed.

Melatonin gummies at 3 to 10 milligrams

Wrong dose for the mechanism, marketing-driven format, and third-party testing has shown actual melatonin content in OTC gummies varies from 17 percent to 478 percent of the label claim across products tested by ConsumerLab. The product category exists because the format sells, not because the mechanism is sound.

PM combination formulations

Tylenol PM, Advil PM, NyQuil, ZzzQuil. These stack acetaminophen, ibuprofen, or dextromethorphan with diphenhydramine. The combination is marketing logic, not therapeutic logic. If you need pain relief, take pain relief. Do not take a sleep aid with it nightly.

Generic sleep stacks with proprietary blends

If the label reads "500mg proprietary blend" instead of listing individual ingredient doses, you cannot evaluate the product. Walk away. Proprietary-blend labelling exists to obscure under-dosing of the named ingredients.

High-dose CBD products marketed for sleep

CBD regulation in the US is currently poor, third-party testing has shown wide variance between label and actual content, and the evidence base for sleep specifically is thin. Expensive, opaque, marketed past the data. The honest version is in the deep-dive.

GABA supplements taken orally

GABA does not cross the blood-brain barrier in any meaningful amount. The receptor target is in the brain. The supplement is in your gut. The mechanism that would connect them is not the mechanism printed on the bottle.

Long-term benzodiazepines for insomnia

Defensible for short-course crisis use. Indefensible as a chronic prescription. Tolerance plus dependence plus withdrawal-driven insomnia that is worse than the baseline that brought the patient in. The full version is in our CBT-I versus sleeping pills piece.

GABA across the blood-brain barrier is a known unsolved problem in pharmacology. The supplement bottle has solved it on the label.

When pharmacology is the right answer

Snerva is not anti-medication. Snerva is anti-misuse. There are several situations where the right medication, at the right dose, for a defined window, is the correct choice — sometimes the obviously correct choice.

Acute insomnia driven by an identifiable stressor

Grief, an acute medical event, a deadline, jet lag, the first weeks of a new shift schedule. A two- to four-week course of a Z-drug or a short-acting orexin antagonist, under medical supervision, with a behavioral plan to follow. The medication is the bridge; the behavioral work is the destination. The trajectory is covered in our acute vs chronic insomnia article.

Severe insomnia while CBT-I is being initiated

When function is impaired — work safety, driving, severe mood deterioration — a short-course bridge is reasonable. The medication should be discontinued as the behavioral protocol takes hold, not run in parallel indefinitely.

Targeted circadian-disorder treatment

Low-dose melatonin (0.3 to 0.5 milligrams) timed four to six hours before target bedtime is the evidence-based intervention for delayed sleep phase disorder and a useful element in jet lag protocols. This is a specific, mechanism-matched use that has nothing to do with the bedtime dose most users default to.

Insomnia secondary to depression or anxiety

When the primary condition responds to SSRI or SNRI treatment, the sleep often follows. The first four to six weeks of SSRI titration commonly worsen sleep, which is the reason patients abandon treatment before the gains arrive. Adjunctive support during that window is the standard of care.

Insomnia in older adults

Pharmacology requires extra caution after age sixty-five but is not ruled out. Low-dose doxepin (3 to 6 milligrams) and the orexin antagonists are reasonable first choices over benzodiazepines or Z-drugs, which carry fall risk and confusion risk in this population. The choice is not whether to medicate. It is what to medicate with.

A pill that puts you to sleep tonight is occasionally the right tool. A pill that puts you to sleep tonight for the next two years almost never is.

The supplement industry asterisk

Almost everything in tier 3 and tier 4 of the framework is a supplement, and the supplement industry deserves its own paragraph.

Supplements are regulated by the FDA in the United States, the MHRA in the UK, and EFSA in the EU — and the word "regulated" is doing a lot of work in that sentence. In practice, supplement labels can be wrong, contaminants can be present, the active ingredient can be misrepresented in either direction, and there is no pre-market approval analogous to the pharmaceutical approval process. Companies cannot legally claim to cure diseases. They can claim almost everything else.

Third-party testing labs (ConsumerLab, NSF, USP) regularly publish reports showing that twenty to forty percent of supplement products they test fail to match the label in some material respect — wrong dose, contamination, missing ingredient. Some categories are worse. Melatonin gummies have been the most variable.

If you are going to take a sleep supplement, take third-party-tested brands — Thorne, Pure Encapsulations, NOW Foods, Designs for Health, Pure Synergy — and ignore Amazon's bestseller list. The bestseller list selects for marketing budget, not for what is in the bottle. The brand premium of a tested product is roughly twenty percent and is the only product feature actually correlated with outcome.

The supplement industry is regulated only in the sense that it cannot legally claim to cure diseases. It can claim everything else.

What to do this week

Four reader profiles, four different next steps.

If you currently take melatonin

Pause. Read the melatonin deep-dive. If you are using it for sleep onset rather than for circadian phase shifting, you are using the wrong drug. If you are using a 5 or 10 milligram product at bedtime, you are using the wrong dose at the wrong time. Both are fixable this week without seeing a doctor.

If you are on long-term Z-drugs or benzodiazepines

Do not stop on your own. Chronic benzodiazepine cessation can produce seizures and is medically dangerous. Read our CBT-I versus sleeping pills piece. Bring the framing to your prescriber. Begin a clinician-supervised taper in parallel with starting a behavioral protocol. The taper runs months, not days.

If you are considering trying a supplement

Read the relevant deep-dive before buying — magnesium, CBD, or the OTC ranking, depending on what you are looking at. Most supplement decisions are made in the wrong order. Read first, buy second.

If you have not tried substances yet

Do not start with substances. Start with stimulus control and sleep restriction — our sleep restriction therapy guide is the entry point. Substances belong, at most, on the second page of the treatment plan. The first page is behavioral. The second page is rarely needed if the first page is run well.

Frequently asked questions

Tools for this topic

Continue reading